Spots Global Cancer Trial Database for Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine
Official Title: A Phase I/II Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine in Patients With Metastatic Hormone-Refractory Prostate Cancer
Study ID: NCT00140348
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate clinical and laboratory safety in patients receiving 4 different doses of GVAX® Prostate Cancer Vaccine in order to determine a maximum tolerated dose.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
South Orange County Medical Research Center, Laguna Woods, California, United States
UCSF, San Francisco, California, United States
West Coast Clinical Research, Tarzana, California, United States
South Florida Medical Research, Aventura, Florida, United States
Emory University, Atlanta, Georgia, United States
Carle Cancer Center, Urbana, Illinois, United States
Northeast Indiana Research, Fort Wayne, Indiana, United States
University of Michigan Medical Center, Ann Arbor, Michigan, United States
Fox Chase cancer Center, Philadelphia, Pennsylvania, United States
Urology San Antonio, San Antonio, Texas, United States
Virginia Mason Med. Crt., Seattle, Washington, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
